Tissue repair researcher TISSIUM secures $60 million financing

Johnson & Johnson
Medtronic Plc

Johnson & Johnson

JNJ

0.00

Medtronic Plc

MDT

0.00

June 24 (Reuters) - Medical researcher TISSIUM said on Wednesday it had secured a $60 million financing deal to support the commercialisation and pipeline expansion of its tissue repair technology.

European Investment Bank to provide up to €30 million with an additional €30 million secured by Series D2 financing.

  • Financing follows U.S. FDA approval last year of its first product, Coaptium Connect, a stitch‑free system that uses dissolvable sleeves and medical glue to reconnect damaged nerves.

  • The technology uses biocompatible polymers that enable minimally invasive tissue repairs and faster recovery times, an approach not currently pursued by major players such as Johnson & Johnson JNJ.N or Medtronic MDT.N.

  • Latest funding brings the total raised by TISSIUM to $260 million since its inception in 2013.

  • The privately owned company is based in Paris and Cambridge, Massachusetts.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.